Terms: = Ovarian cancer AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA AND Treatment
4 results:
1. Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.
Habel A; Weili X; Hadj Ahmed M; Stayoussef M; Bouaziz H; Ayadi M; Mezlini A; Larbi A; Yaacoubi-Loueslati B
Int J Biol Markers; 2023 Dec; 38(3-4):203-213. PubMed ID: 37518940
[TBL] [Abstract] [Full Text] [Related]
2. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
3. High expression of herpesvirus entry mediator (hvem) in ovarian serous adenocarcinoma tissue.
Fang Y; Ye L; Zhang T; He QZ; Zhu JL
J BUON; 2017; 22(1):80-86. PubMed ID: 28365939
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
Menotti L; Cerretani A; Hengel H; Campadelli-Fiume G
J Virol; 2008 Oct; 82(20):10153-61. PubMed ID: 18684832
[TBL] [Abstract] [Full Text] [Related]
